{"id":"556962-5345","orgnr":"556962-5345","name":"Saniona AB","name_registered_on":"2014-02-19","legal_form":{"code":"AB","name":"Aktiebolag"},"status":"registered","registered_on":"2014-02-19","business_description":"Föremålet för bolagets verksamhet skall vara att utveckla läkemedel och därmed förenlig verksamhet samt att äga och förvalta aktier.","industries":[{"code":"21200","name":"Tillverkning av läkemedel"}],"postal_address":{"street":"Åldermansgatan 10","care_of":"c/o Innecta AB","postal_code":"22764","city":"LUND","country":"SE","municipality":{"code":"1281","name":"Lund"},"county":{"code":"12","name":"Skåne län"}},"registered_office":{"municipality":{"code":"1280","name":"Malmö"},"county":{"code":"12","name":"Skåne län"}},"activity_status":"active","employee_class":{"code":"1","name":"0 anställda"},"turnover_class":{"code":"3","name":"1 000 - 4 999 tkr","year":2025},"public_company":{"code":"23","name":"Publikt, Stockholm Small Cap"},"f_tax":"registered","vat":"registered","employer":"registered","registry_source":{"dataset":"bolagsverket_bulkfil","published_on":"2026-11-09"},"annual_reports":[{"from":"2024-01-01","to":"2024-12-31","framework":"IFRS","documents":{},"source":{"dataset":"esef","file":"/549300XO4L9XNOCFCZ84/2024-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2024-12-31-0-sv.zip","url":"https://filings.xbrl.org/549300XO4L9XNOCFCZ84/2024-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2024-12-31-0-sv/reports/ixbrlviewer.html"}},{"from":"2023-01-01","to":"2023-12-31","framework":"IFRS","documents":{},"source":{"dataset":"esef","file":"/549300XO4L9XNOCFCZ84/2023-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2023-12-31-sv.zip","url":"https://filings.xbrl.org/549300XO4L9XNOCFCZ84/2023-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2023-12-31-sv/reports/ixbrlviewer.html"}},{"from":"2022-01-01","to":"2022-12-31","framework":"IFRS","documents":{},"source":{"dataset":"esef","file":"/549300XO4L9XNOCFCZ84/2022-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2022-12-31-sv.zip","url":"https://filings.xbrl.org/549300XO4L9XNOCFCZ84/2022-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2022-12-31-sv/reports/ixbrlviewer.html"}},{"from":"2021-01-01","to":"2021-12-31","framework":"IFRS","documents":{},"source":{"dataset":"esef","file":"/549300XO4L9XNOCFCZ84/2021-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2021-12-31-se.zip","url":"https://filings.xbrl.org/549300XO4L9XNOCFCZ84/2021-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2021-12-31-se/reports/ixbrlviewer.html"}}],"latest_financials":{"from":"2024-01-01","to":"2024-12-31","scope":"group","currency":"SEK","net_sales":334672000,"operating_profit":241885000,"profit_after_financial_items":207021000,"net_profit":188706000,"total_assets":339733000,"equity":231818000,"long_term_liabilities":2622000,"current_liabilities":105293000,"cash":303258000,"staff_costs":37787000,"net_sales_growth":18.874,"source":{"annual_report":"2024-12-31","document":"https://filings.xbrl.org/549300XO4L9XNOCFCZ84/2024-12-31/ESEF/SE/0/549300XO4L9XNOCFCZ84-2024-12-31-0-sv/reports/ixbrlviewer.html"},"anchors":{"cash":{"fact":"f1__s2__3__16"},"current_liabilities":{"fact":"f1__s2__3__42"},"equity":{"fact":"f1__s2__3__27"},"long_term_liabilities":{"fact":"f1__s2__3__33"},"net_profit":{"fact":"f1__s1__3__19"},"net_sales":{"fact":"f1__s1__3__5"},"operating_profit":{"fact":"f1__s1__3__13"},"profit_after_financial_items":{"fact":"f1__s1__3__17"},"staff_costs":{"fact":"f1__s1__3__10"},"total_assets":{"fact":"f1__s2__3__20"}}}}